Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and chemotherapeutic resistant disease, which is virtually incurable with current treatment modalities. Unlike other solid cancers, pancreatic cancer treatment has not improved significantly in the last thirty years. With limited molecular targets, there is an urgent need to discover new therapies to improve the outcome of the patients. We proposed to develop novel monoclonal antibodies through hybridoma technology to identify candidate proteins associated with PDAC that may represent potential molecular therapeutic targets. Using a combination of established PDAC cell lines, novel patient derived xenograft (PDX) material and patient tumours as immunogenic material, we successfully established hybridomas reacting to their respective immunogens. One lead hybridoma candidate, mAb 4A5 raised against PANC-1 and PIN 127 PDX derived cells, secreted an IgG-kappa monoclonal antibody. It was characterised and found to react with a protein potentially in higher abundance in PDAC of approximately 60 kDa. In regards to the potential functional effects of mAb 4A5, our study demonstrated that it has no effect on the proliferation of PANC-1 and PIN 127 cells. Despite advances in the field of hybridoma generation, fusion technology is still the preferred method for monoclonal antibody development. BriCloneTM is a well-established hybridoma growth supplement, added at the post-fusion step in order to improve formation of hybridoma colonies. Whilst very effective, this product contains fetal bovine serum and hence can show batch-to-batch variation. The second strand of the thesis focused on the development of a serum-free hybridoma growth supplement for enhancing the generation of hybridoma post fusion. A robust and reliable product was developed, which demonstrated similar to better performances compared to BriCloneTM. Thirdly, in order to eliminate the use of mice in the quality control testing of BriCloneTM, it was proposed to create an in vitro cell based assay that would display the potency of BriCloneTM. While no effective reliable assay was achieved, there is plenty of scope for more research to find an adequate test.